Meagan Parrish
Lead Editor at Industry Dive
Lead Editor at PharmaVOICE
Senior editor for @industrydive, follower of the pharma world, proud mama, frequent flyer, occasional belly dancer.
Articles
-
2 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The days of animal testing in pharma could be dwindling as regulators push toward alternative models. This week, the NIH announced an initiative to adopt “innovative, human-based science” to limit the use of animals. “For decades, our biomedical research system has relied heavily on animal models. With this initiative, NIH is ushering in a new era of innovation,” NIH Director Dr. Jay Bhattacharya said in a statement.
-
3 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. A sudden halt in funding from the National Institutes of Health has resonated deeply through America’s scientific research world. For many, the cuts have had a direct impact — from lost jobs to closed labs to halted clinical trials.
-
4 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. A lot is riding on the upcoming results for Compass Pathways’ psilocybin-based depression treatment.
-
1 month ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. What started as the shocking murder of a healthcare executive has now become a watershed moment for an entire industry. Brian Thompson, the CEO of UnitedHealthcare, was gunned down in December while walking along a Manhattan sidewalk. After an intense manhunt, the suspected assailant was caught and identified as Luigi Mangione. The case against 26-year-old Mangione, which includes state and federal charges, is moving swiftly.
-
1 month ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The U.S.’s billowing trade policies rattled global markets this week with the onset of new tariffs that were then mostly paused. Although the uncertainty took a bite out of Big Pharma stocks, the industry was mostly spared from the worst of the upheaval.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 295
- Tweets
- 110
- DMs Open
- No
Recently caught up with SIGA Technologies, one of the sole producers of a monkeypox treatment, to find out how they're preparing for the potential of an ongoing outbreak. Here's my report: https://t.co/jFudmaQuQh
There are a host of reasons pharma could get its M&A groove back in 2022. Here's a look at some of the leading market factors on the pharma M&A scene. https://t.co/KsO1vfnZlE
For one of my first PharmaVoice articles, I picked a really interesting company to write about. With a novel platform and innovative vaccines, @vaxxinity is worth having on your pharma radar. https://t.co/sUmGTUcFPp